ArticleCardiovascular research2025
Age-dependent remodelling of arterial chemoafferent innervation in hypertension.
Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exacerbated ATP transmission in the carotid body is linked to glomus cell expansion in spontaneously hypertensive rats.The Journal of physiology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
aimsElevated sympathetic nerve activity (eSNA) is a hallmark of cardiovascular disease and represents an important clinical target for disease management. A known driver of eSNA is aberrant signalling from, and sensitization of, the carotid body (CB) arterial chemoreceptors. Sensitization is coupled with CB hypertrophy, the cause of which remains unclear. Here, we set out to characterize the morphological basis of CB hypertrophy in hypertension to understand its aberrant activity. METHODS AND
resultsUsing high-throughput fluorescence microscopy, we mapped the neurovascular interface and chemoafferent innervation of the CB of spontaneously hypertensive rats (SHR) across multiple age groups. We show that CB hypertrophy driven by chemosensory (type I) cell hyperplasia and an expanded vascular network is evident in 4-6-week-old SHR without established hypertension. Specifically, CB hypertrophy in the SHR is linked to increased chemoafferent innervation and an age-dependent remodelling of nerve fibre composition.
conclusionsCB hypertrophy in hypertension is associated with chemosensory hyperplasia and angiogenesis, likely mediated by impaired HIF-PHD signalling in the SHR. We propose that CB size may serve as a candidate marker of chemoafferent sensitivity and the efficacy of therapies targeting the CB. However, further validation in humans is needed to support this link. Neurotrophic pathways promoting increased chemoafferent innervation in hypertension are proposed as a potential target for modulating CB activity in sympathetically mediated diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.